January 26, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval
Shaman Pharma is creating an umbrella for the convergence of licensed cannabis and psychedelic companies by developing and acquiring novel psychedelic businesses. Their mission is to accelerate science-based, legal drug innovation targeting mind expansion, medical therapy, and informed adult uses.
Shaman is working to lead the industry in all psychoactive molecules. As part of their Narcotics Dealer’s License, Health Canada just granted Shaman authorization for Psilocybin, the psychoactive molecule found in “magic mushrooms.” Along with previously authorized ketamine and cannabis, they are now approved for 20 controlled substances.
Shaman is ready for rapid growth:
- Licensed by Health Canada to legally handle, import and export narcotic drugs
- Operates a fully staffed and equipped cGMP lab with world-class scientists
- Generates revenues & near-term EBITDA from Big Pharma partnerships
Shaman’s convergence model goes beyond vertical integration to deliver multi-channel revenue from any regulated, controlled substance. With the market poised to grow 16.3% per year and reach $6.8 billion by 2027, the legal renaissance of psychedelic drugs is booming.
Join our webinar Tuesday, January 26 to hear from Shaman Pharma CEO, Alex Grenier, and why his company is poised to profit from this fast growing sector.
All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.